Skip to main content
Disc Medicine, Inc. logo

Disc Medicine, Inc. — Investor Relations & Filings

Ticker · IRON ISIN · US36870G1058 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2024-04-02 Regulatory Filings
Country US United States of America
Listing US IRON

About Disc Medicine, Inc.

https://www.discmedicine.com/

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious hematologic diseases. The company's research focuses on fundamental pathways of red blood cell biology to address a range of disorders. Its pipeline includes bitopertin, an investigational therapy for erythropoietic protoporphyria (EPP) for which a New Drug Application has been submitted for accelerated approval. Other clinical-stage programs are evaluating treatments for myelofibrosis-associated anemia and other conditions involving ineffective erythropoiesis.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 1, 2024, by Disc Medicine, Inc. It reports topline results from a Phase 2 clinical study (AURORA Study) and mentions a press release attached as Exhibit 99.1. The text includes detailed clinical trial results and a summary of findings, but it is primarily an announcement of these results rather than a full financial or management report. The document also references a conference call and a corporate presentation available on the company's website. The length is about 10,490 characters, which is relatively short for a full detailed report. The content is focused on clinical trial topline results and a press release rather than comprehensive financial data or management discussion. Therefore, this filing is best classified as a Regulatory Filing (RNS) because it is a current report announcing clinical trial results and a press release, not a full financial report or earnings release. It does not fit the Earnings Release (ER) category because it is not primarily about quarterly financial results but clinical study results. It is not a Management Report or Annual Report. Hence, the most appropriate classification is Regulatory Filings (RNS).
2024-04-02 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Disc Medicine, Inc. It registers additional shares of common stock under the company's stock option and employee stock purchase plans, including inducement awards. The document includes detailed information about the plans, share increases, and indemnification provisions for directors and officers. It is a registration statement related to securities issuance and employee benefit plans, not a financial report, earnings release, or management discussion. Form S-8 filings are specifically for registering securities to be offered under employee benefit plans and are distinct from other report types like Annual Reports or Capital Updates. Therefore, the document fits the category of a Regulatory Filing (RNS) as it is a regulatory compliance filing that does not fit other specific categories.
2024-03-21 English
10-K
Annual Report FY 2023
2024-03-21 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed by Disc Medicine, Inc. to announce financial results for the fourth quarter and fiscal year ended December 31, 2023. The document itself serves as a vehicle to furnish a press release (Exhibit 99.1) regarding these results. Per the filing definitions and rules, a Form 8-K that announces financial results via an attached press release is classified as an Earnings Release (ER).
2024-03-21 English
Director's Dealing 2024
Director's Dealing
2024-03-07 English
Regulatory Filings 2024
Regulatory Filings
2024-03-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.